









Markets
/
Stocks
/
nasdaq-nxl
/

Nexalin Technology Inc

NXL

1.320USD

-0.060-4.35%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

22.99MMarket Cap

LossP/E TTM



Nexalin Technology Inc

1.320

-0.060-4.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Nexalin Technology Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Nexalin Technology Inc's Score

Industry at a Glance

Industry Ranking

110 / 210

Overall Ranking

244 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+172.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Nexalin Technology Inc Highlights

StrengthsRisks

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Growing

The company is in a growing phase, with the latest annual income totaling USD 168.72K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 168.72K.

Fairly Valued

The company’s latest PE is -1.82, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.31M shares, increasing 34.63% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 159.88K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.05.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.94, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 70.59K, representing a year-over-year increase of 163.00%, while its net profit experienced a year-over-year increase of 23.08%.

Score

Industry at a Glance

Previous score

6.94

Change



Financials

7.42

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.78

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.64

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.46

Key Metrics

Free cash flow

No Data

Nexalin Technology Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.99, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -1.82, which is -75.01% below the recent high of -0.45 and -264.29% above the recent low of -6.62.

Score

Industry at a Glance

Previous score

7.99

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Nexalin Technology Inc is 4.00, with a high of 4.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+189.86%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Nexalin Technology Inc

NXL

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 6.95, which is higher than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 1.85 and the support level at 1.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.53

Change

-0.58

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.070

Neutral

RSI(14)

48.642

Neutral

STOCH(KDJ)(9,3,3)

18.601

Sell

ATR(14)

0.142

Low Volatility

CCI(14)

-190.488

Sell

Williams %R

88.095

Oversold

TRIX(12,20)

1.291

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.440

Sell

MA10

1.463

Sell

MA20

1.453

Sell

MA50

1.137

Buy

MA100

1.065

Buy

MA200

1.557

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 7.20%, representing a quarter-over-quarter decrease of 56.45%. The largest institutional shareholder is The Vanguard, holding a total of 159.88K shares, representing 0.88% of shares outstanding, with 9.89% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Elson (Marilyn)

1.54M

MYDA Advisors LLC

800.00K

Hu (Benjamin)

377.10K

+10.70%

White (Mark)

309.13K

Owens (David)

185.75K

+24.42%

The Vanguard Group, Inc.

Star Investors

159.88K

Geode Capital Management, L.L.C.

116.37K

+2.01%

Kazden (Alan)

83.13K

Bernhard (Leslie)

49.84K

Renaissance Technologies LLC

Star Investors

46.34K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.16, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.